Efficacy, safety, and quality of life in patients aged ≥75 years in MIRASOL (GOG 3045/ENGOT-ov55): mirvetuximab soravtansine vs investigator’s choice chemotherapy in folate receptor alpha-positive platinum-resistant ovarian cancer

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Annamaria Ferrero, Felix Hilpert, Michael A. Gold, Laurence Gladieff, Cueva Jf, Robert Morris, Lucy Mc Avan, Ramey D. Littell, Jung-Yun Lee, Domenica Lorusso, Vincent Renard, Mary E. Gordinier
+8 more Dagmara Klasa-Mazurkiewicz, Jacqueline M. Tromp, Mario Beiner, Lynne M. Knowles, Coriolan Lebreton, Yajun Emily Zhu, Jérôme Alexandre, Sarah Crafton
DOI: 10.1016/j.ijgc.2025.104427
Cited by: 2

Fields of Study & Subjects

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment Advanced Breast Cancer Therapies

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
2
Pages
104427–104427
Publication date
1 February 2026
Language
EN